HOME >> BIOLOGY >> NEWS
Tigecycline - antibiotic evaluated in surveillance trial

International Health Management Associates, Inc. (IHMA) has been commissioned to conduct the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), a global in vitro surveillance study for tigecycline, a broad-spectrum antibiotic currently under investigation. The study will evaluate the activity of tigecycline against a variety of bacteria, including strains resistant to currently approved drugs, at approximately 690 hospitals in approximately 35 countries over the next three years. Tigecycline is an injectable glycylcycline, a new class of antibiotics, being developed by Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

"T.E.S.T. is likely one of the largest surveillance studies of its kind ever undertaken. The trial will evaluate the activity of tigecycline against a wide range of clinical pathogens collected from diverse patient populations worldwide. Almost all bacterial strains have developed some level of antibiotic resistance, so this study will enable us to document with in vitro laboratory data the activity of this new antibiotic against bacterial pathogens, including those exhibiting multiple antibiotic resistance," said Daryl Hoban, Ph.D., Director of Clinical and Laboratory Services.

About T.E.S.T.
T.E.S.T. investigators will collect and evaluate clinically significant isolates from a variety of infection sites. The isolates will be tested in vitro to evaluate the activity of tigecycline compared with currently available antimicrobial agents.

The T.E.S.T. data will build upon the drug's in vitro data collected in ongoing Phase 2 and Phase 3 clinical trials in patients. Phase 2 clinical trials investigated use of tigecycline to treat complicated skin and skin-structure or complicated intra-abdominal infections. Phase 3 clinical trials are nearing completion. Laboratory tests from clinical trials have examined tigecycline's activity against a broad spectrum of pathogens, including gram-positive, gram
'"/>

Contact: Jennifer Petra
jpetra@porternovelli.com
212-601-8110
Porter Novelli
19-May-2004


Page: 1 2

Related biology news :

1. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
2. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
3. Smart antibiotics may result from UCLA research
4. K-State researcher working to improve alternatives to equine antibiotics
5. Bacterial protein recycling factor possible key to new class of antibiotics
6. Bacteria spill their guts to aid researchers in quest for new antibiotics
7. Molecule that blocks key bacterial enzyme may lead to new antibiotics
8. Does antibiotic use contribute to allergies?
9. Data show investigational antibiotic safe, effective in preventing travelers diarrhea
10. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study
11. New York microbiologists awarded research grants in antibiotic resistance and lyme disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/4/2019)... ... April 02, 2019 , ... ... solutions for drugs, biologics and consumer health products, today announced that it will ... at the Gaylord National Harbor Hotel, Oxon Hill, Maryland, on April 10-12, 2019. ...
(Date:4/4/2019)... ... April 02, 2019 , ... The live session ... into the connectivity between product risk management (ISO 14971) and the clinical risk ... process. , With increasing global regulation and reimbursement challenges faced by medical device ...
(Date:4/4/2019)... ... April 03, 2019 , ... R3 Stem Cell ... its nationwide Centers of Excellence. R3 wants patients to feel secure when they ... protect patients from Centers that use inferior regenerative biologics, protocols or amounts, R3 ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... The AACR annual conference pulls together ... see the most cutting-edge cancer research. The Visikol team will be at the show ... assays as well as their digital pathology services . “For AACR this ...
(Date:3/19/2019)... ... March 19, 2019 , ... Konica Minolta Precision Medicine, ... formation of their inaugural Scientific Advisory Board. , Founded in late ... account individual variability in genes, environment, and lifestyle to more accurately predict, detect, ...
(Date:3/19/2019)... ... March 19, 2019 , ... Cirrascale Cloud Services ®, ... begun offering NVIDIA® DGX-1™ deep learning systems as part of its dedicated, multi-GPU ... highest performance for artificial intelligence and deep learning research and development. , “Our ...
(Date:3/14/2019)... ... 2019 , ... EyeCRO LLC has been awarded full accreditation ... Department of Veterans Affairs, the Oklahoma Medical Research Foundation, Oklahoma State University, and ... to receive this prestigious endorsement. The award letter from AAALAC International stated: ...
Breaking Biology Technology:
Cached News: